CYTEK BIOSCIENCES, INC. Proceeds from Lines of Credit
CYTEK BIOSCIENCES, INC. (CTKB) reported Proceeds from Lines of Credit of $5.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2026-06-30 was $41.00K, a 97.04% decline year-over-year.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2026-03-31 was $5.07M, a 634.49% increase year-over-year.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $1.42M, a 49.16% decline year-over-year.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $2.09M, a 41720.00% increase year-over-year.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2025 was $5.58M, a 33.51% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2024 was $4.18M.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2023 was $0.00.
- CYTEK BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2022 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.11M 10-Q · filed 2026-08-05 | $6.53M derived: sum of 3 quarters · filed 2026-08-05 | $8.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-07 | $6.48M derived: sum of 2 quarters · filed 2026-05-07 | $8.57M derived: sum of 3 quarters · filed 2026-05-07 | $9.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.51M derived: sum of 2 quarters · filed 2026-02-26 | $4.89M derived: sum of 3 quarters · filed 2026-08-05 | $5.58M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.48M derived: sum of 2 quarters · filed 2026-08-05 | $4.17M 10-Q · filed 2025-11-05 | $6.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.08M 10-Q · filed 2026-08-05 | $4.86M derived: sum of 3 quarters · filed 2026-08-05 | $4.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $690.00K 10-Q · filed 2026-05-07 | $3.48M derived: sum of 2 quarters · filed 2026-05-07 | $3.48M derived: sum of 3 quarters · filed 2026-05-07 | $3.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.79M derived: sum of 2 quarters · filed 2026-02-26 | $2.79M derived: sum of 3 quarters · filed 2026-02-26 | $4.18M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.40M 10-Q · filed 2025-11-05 | $1.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.39M 10-Q · filed 2025-08-06 | $1.39M derived: sum of 3 quarters · filed 2026-02-26 | $1.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.39M 10-Q · filed 2025-05-08 | $1.39M derived: sum of 2 quarters · filed 2026-02-26 | $1.39M derived: sum of 3 quarters · filed 2026-02-26 | $1.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |